Correlation of serum PSA and Gleason score in Nigerian men with prostate cancer

http://www.cancer/org/downoads/STT/Global_Cancer_Facts_and_Figures_2007.pdf

Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer. J. Clin. 2005 Mar–Apr. 55(2):74–108.

Lubeck DP, Litwin MS, Henning JM, Stier DM, Mazonson P, Fisk R, et al. The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology. 1996 Nov. 48(5):773–7.

Sun L, Gancarczyk K, Paquette EL, McLeod DG, Kane C, Kusuda L, et al. Introduction to Department of Defense Center for Prostate Disease Research Multicenter National Prostate Cancer Database, and analysis of changes in the PSA-era. Urol. Oncol. 2001;6(5):203–9.

Odedina FT, Ogunbiyi JO, Ukoli FA. Roots of prostate cancer in African-American men. J. Natl. Med. Assoc. 2006 Apr:98(4):539–43.

Gardner WA, Jr, Coffey D, Karr JP, Chiarodo A, Epstein J, McNeal JE, et al. A uniform histopathologic grading system for prostate cancer. Subcommittee on Diagnostic Nomenclature, Prostate Cancer Working Group, Organ systems Program. Hum. Pathol. 1988 Jan;19(1):119–20.

Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen asa serum marker for adenocarcinoma of the prostate. N. Engl. J. Med. 1987 Oct 8;317(15):909–16.

Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J. Urol. 1995 Aug;154(2 Pt 1):407–13.

Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: A decade of discovery—what we have learned and where we are going. J. Urol. 1999 Aug;162(2):293–306.

Guinan P, Bush I, Ray V, Vieth R, Rao R, Bhatti R. The accuracy of the rectal examination in the diagnosis of prostate carcinoma. N. Engl. J. Med. 1980 Aug 28;303(9):499–503.

Ogunbiyi JO, Shittu OB. Increased incidence of prostate cancer in Nigerians. J. Natl. Med. Assoc. 1999 Mar;91(3):159–64.

Abbiyesuku FM, Shittu OB, Oduwole OO, Osotimehin BO. Prostate specific antigen in the Nigerian African. Afr. J. Med. Med. Sci. 2000 Jun;29(2):97–100.

Kirby RS, Christmas TJ, Brawer M. Tumors markers in prostate cancer. In: Kirby RS, Christmas TJ, Brawer M, editors. Prostate cancer. 1st ed. Italy: Mosby; 1996. P.55–64.

Freeman VL, Coard KC, Wojcik E, Durazo Arvizu R. Use of the Gleason system in international comparsions of prostatic adenocarcinomas in blacks. Prostate. 2004 Feb 1;58(2):169–73.

Gleason DF. Histological grading and clinical staging of prostatic carciooma. In: Tannenbaum M, editor. Urologic pathology: The prostate. Philadelphia: Lea & Febiger; 1977. P.171–98.

D'Amico AV, McGovern FT, Church PA, Tempany CMC. The staging of prostate cancer. In: Kantoff PW, Wishnow KL, Loughlin KR, editors: Prostate cancer: A multiisciplinary guide. 1st ed. Massachusetts. Blackwell Scientific; 1997. P.41–56.

Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. 1974. J. Urol. 2002 Feb;167(2) Pt 2): 953–8; discussion 959.

Gleason DF. Histological grading of prostatic carcinoma. In: Bostwick DG, editor. Pathology of the prostate. New Y York: Churchill Livingstone; 1990. P.83–93.

Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J. Natl. Cancer Inst. 2006 Aug 16;98(16):1128–33.

Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J. Urol. 1993 Jul;150(1):110–4.

Herschman JD, Smith DS, Catalona WJ. Effect of ejaculation on serum total and free prostate-specific antigen concentrations. Urology. 1997 Aug;50(2):239–43.

Moul JW, Sesterhenn IA, Connelly RR, Douglas T, Srivastava S, Mostofi FK, et al. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA. 1995 Oct 25;274(16):1277–81.

Amayo A, Obara W. Serum prostate specific antigen levels in men with benign prostatic hyperplasia and cancer of prostate. East Afr. Med. J. 2004; Jan;81(1):22–6.

Iya D, Chanchani S, Belmonte J, Morris D, Glew RH, Van Der Jagt DJA. Prostate specific antigen in Africans: A study in Nigerian men. Nig J. Surg. Res. 2003;5(3):114–9.

The European Randomized study of Screening for Prostate Cancer(ERSPC). January 12, 2008;available at:http://www.erspc.org.

American Urological Association. Prostate cancer screening. 2006. http://www.urologyhealth.org/adult/index.cfm

Efstathiou JA, Chen MH, Catalona WJ, McLeod DG, Carroll PR, Moul JW, et al. Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality. Urology. 2006 Aug;68(2):342–7.

Davidson P. and Gabbay J. Should mass screening for prostate cancer be introduced at the national level? WHO Regional Office for Europe Health Evidence Network (HEN), May 2004.